5ggu - Revision history

OCA at 11:31, 2 August 2023

2023-08-02T11:31:13Z

←Older revision		Revision as of 11:31, 2 August 2023
Line 3:		Line 3:
	<StructureSection load='5ggu' size='340' side='right'caption='[[5ggu]], [[Resolution\|resolution]] 2.29Å' scene=''>		<StructureSection load='5ggu' size='340' side='right'caption='[[5ggu]], [[Resolution\|resolution]] 2.29Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5ggu]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5GGU OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://proteopedia.org/fgij/fg.htm?mol=5GGU FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5ggu]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5GGU OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5GGU FirstGlance]. <br>
-	</td></tr><tr id='~~related~~'><td class="sblockLbl"><b>[[~~Related_structure~~\|~~Related~~:]]</b></td><td class="sblockDat">~~[[5ggv\|5ggv]]~~, [[~~5ggt~~\|~~5ggt]], [[5ggs\|5ggs]], [[5ggr\|5ggr]], [[5ggq\|5ggq~~]]</td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.292Å</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://proteopedia.org/fgij/fg.htm?mol=5ggu FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5ggu OCA], [~~http~~://pdbe.org/5ggu PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=5ggu RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/5ggu PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=5ggu ProSAT]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5ggu FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5ggu OCA], [https://pdbe.org/5ggu PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5ggu RCSB], [https://www.ebi.ac.uk/pdbsum/5ggu PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5ggu ProSAT]</span></td></tr>
	</table>		</table>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
Line 20:		Line 20:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Heo~~, Y S]]~~	+	[[Category: Heo YS]]
-	~~[[Category: Antibody]]~~	+
-	~~[[Category: Immune system~~]]	+

OCA at 06:42, 13 May 2020

2020-05-13T06:42:31Z

←Older revision		Revision as of 06:42, 13 May 2020
Line 1:		Line 1:

	==Crystal structure of tremelimumab Fab==		==Crystal structure of tremelimumab Fab==
-	<StructureSection load='5ggu' size='340' side='right' caption='[[5ggu]], [[Resolution\|resolution]] 2.29Å' scene=''>	+	<StructureSection load='5ggu' size='340' side='right'caption='[[5ggu]], [[Resolution\|resolution]] 2.29Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5ggu]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5GGU OCA]. For a <b>guided tour on the structure components</b> use [http://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5GGU FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5ggu]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5GGU OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=5GGU FirstGlance]. <br>
	</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5ggv\|5ggv]], [[5ggt\|5ggt]], [[5ggs\|5ggs]], [[5ggr\|5ggr]], [[5ggq\|5ggq]]</td></tr>		</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5ggv\|5ggv]], [[5ggt\|5ggt]], [[5ggs\|5ggs]], [[5ggr\|5ggr]], [[5ggq\|5ggq]]</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5ggu FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5ggu OCA], [http://pdbe.org/5ggu PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5ggu RCSB], [http://www.ebi.ac.uk/pdbsum/5ggu PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5ggu ProSAT]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=5ggu FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5ggu OCA], [http://pdbe.org/5ggu PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5ggu RCSB], [http://www.ebi.ac.uk/pdbsum/5ggu PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5ggu ProSAT]</span></td></tr>
	</table>		</table>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
Line 20:		Line 20:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Large Structures]]
	[[Category: Heo, Y S]]		[[Category: Heo, Y S]]
	[[Category: Antibody]]		[[Category: Antibody]]
	[[Category: Immune system]]		[[Category: Immune system]]

OCA at 19:47, 9 December 2016

2016-12-09T19:47:06Z

←Older revision		Revision as of 19:47, 9 December 2016
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 5ggu is ~~ON HOLD until Paper~~ Publication	+	==Crystal structure of tremelimumab Fab==
		+	<StructureSection load='5ggu' size='340' side='right' caption='[[5ggu]], [[Resolution\|resolution]] 2.29Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[5ggu]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5GGU OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5GGU FirstGlance]. <br>
		+	</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5ggv\|5ggv]], [[5ggt\|5ggt]], [[5ggs\|5ggs]], [[5ggr\|5ggr]], [[5ggq\|5ggq]]</td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5ggu FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5ggu OCA], [http://pdbe.org/5ggu PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5ggu RCSB], [http://www.ebi.ac.uk/pdbsum/5ggu PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5ggu ProSAT]</span></td></tr>
		+	</table>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Cancer cells express tumour-specific antigens derived via genetic and epigenetic alterations, which may be targeted by T-cell-mediated immune responses. However, cancer cells can avoid immune surveillance by suppressing immunity through activation of specific inhibitory signalling pathways, referred to as immune checkpoints. In recent years, the blockade of checkpoint molecules such as PD-1, PD-L1 and CTLA-4, with monoclonal antibodies has enabled the development of breakthrough therapies in oncology, and four therapeutic antibodies targeting these checkpoint molecules have been approved by the FDA for the treatment of several types of cancer. Here, we report the crystal structures of checkpoint molecules in complex with the Fab fragments of therapeutic antibodies, including PD-1/pembrolizumab, PD-1/nivolumab, PD-L1/BMS-936559 and CTLA-4/tremelimumab. These complex structures elucidate the precise epitopes of the antibodies and the molecular mechanisms underlying checkpoint blockade, providing useful information for the improvement of monoclonal antibodies capable of attenuating checkpoint signalling for the treatment of cancer.

-	~~Authors:~~ Heo, Y.S.	+	Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy.,Lee JY, Lee HT, Shin W, Chae J, Choi J, Kim SH, Lim H, Won Heo T, Park KY, Lee YJ, Ryu SE, Son JY, Lee JU, Heo YS Nat Commun. 2016 Oct 31;7:13354. doi: 10.1038/ncomms13354. PMID:27796306<ref>PMID:27796306</ref>

-	~~Description: Crystal structure~~ of ~~tremelimumab Fab~~	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	[[Category: ~~Unreleased Structures~~]]	+	</div>
-	[[Category: ~~Heo, Y.S~~]]	+	<div class="pdbe-citations 5ggu" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Heo, Y S]]
		+	[[Category: Antibody]]
		+	[[Category: Immune system]]

OCA at 21:32, 12 July 2016

2016-07-12T21:32:11Z

←Older revision		Revision as of 21:32, 12 July 2016
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 5ggu is ON HOLD	+	The entry 5ggu is ON HOLD until Paper Publication

	Authors: Heo, Y.S.		Authors: Heo, Y.S.

-	Description: tremelimumab Fab	+	Description: Crystal structure of tremelimumab Fab
	[[Category: Unreleased Structures]]		[[Category: Unreleased Structures]]
	[[Category: Heo, Y.S]]		[[Category: Heo, Y.S]]

OCA: Protected "5ggu" [edit=sysop:move=sysop]

2016-06-23T18:42:16Z

Protected "5ggu" [edit=sysop:move=sysop]

←Older revision

Revision as of 18:42, 23 June 2016

OCA: New page: '''Unreleased structure''' The entry 5ggu is ON HOLD Authors: Heo, Y.S. Description: tremelimumab Fab Category: Unreleased Structures Category: Heo, Y.S

2016-06-23T18:42:14Z

New page: '''Unreleased structure''' The entry 5ggu is ON HOLD Authors: Heo, Y.S. Description: tremelimumab Fab Category: Unreleased Structures Category: Heo, Y.S

New page

'''Unreleased structure'''

The entry 5ggu is ON HOLD

Authors: Heo, Y.S.

Description: tremelimumab Fab
[[Category: Unreleased Structures]]
[[Category: Heo, Y.S]]